Topic: heart failure


8. Praliciguat

Cyclerion Therapeutics was just a few months on from its spinout from Ironwood Pharma when it was forced to abandon a key indication for one of its lead drugs—soluble guanylate cyclase (sGC) stimulator praliciguat—prompting it to ax more than one-fifth of its workforce.

4. Entresto

There is great hope that Entresto might be effective in HFpEF, which accounts for around half of all heart failure cases. As it turned out, the PARAGON-HF trial of Entresto in HFpEF proved to be something of a disappointment, missing its main goal of reducing deaths and emergency hospitalizations.